Today's drug approval system is built to treat disease, not prevent it. With no agreed-upon endpoints for preventive indications, promising therapies for conditions like Alzheimer's and osteoarthritis stall. As AI speeds up the validation of new endpoints, we will discuss the regulatory and reimbursement paths that could make prevention investable.